Technical Analysis for IMMX - Immix Biopharma, Inc.

Grade Last Price % Change Price Change
C 1.82 7.06% 0.12
IMMX closed up 7.06 percent on Wednesday, November 20, 2024, on 3.7 times normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Outside Day Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 7.06%
Pocket Pivot Bullish Swing Setup 7.06%
Inside Day Range Contraction 7.06%
BB Squeeze Ended Range Expansion 7.06%

   Recent Intraday Alerts

Alert Time
Upper Bollinger Band Resistance about 18 hours ago
Up 10% about 21 hours ago
Up 1 ATR about 21 hours ago
60 Minute Opening Range Breakout about 21 hours ago
Rose Above Upper Bollinger Band about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma

Is IMMX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.75
52 Week Low 1.26
Average Volume 118,911
200-Day Moving Average 2.22
50-Day Moving Average 1.63
20-Day Moving Average 1.67
10-Day Moving Average 1.71
Average True Range 0.16
RSI (14) 58.85
ADX 20.34
+DI 28.97
-DI 14.23
Chandelier Exit (Long, 3 ATRs) 1.48
Chandelier Exit (Short, 3 ATRs) 1.95
Upper Bollinger Bands 1.83
Lower Bollinger Band 1.50
Percent B (%b) 0.96
BandWidth 19.73
MACD Line 0.02
MACD Signal Line 0.01
MACD Histogram 0.0113
Fundamentals Value
Market Cap 46.47 Million
Num Shares 25.5 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -1.98
Price-to-Sales 0.00
Price-to-Book 4.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.25
Resistance 3 (R3) 2.24 2.08 2.18
Resistance 2 (R2) 2.08 1.97 2.09 2.15
Resistance 1 (R1) 1.95 1.91 2.02 1.96 2.13
Pivot Point 1.80 1.80 1.83 1.80 1.80
Support 1 (S1) 1.67 1.69 1.73 1.68 1.51
Support 2 (S2) 1.51 1.62 1.52 1.49
Support 3 (S3) 1.38 1.51 1.46
Support 4 (S4) 1.39